Rituximab reduces joint damage in RA patients

    loading  Checking for direct PDF access through Ovid


Results from the REFLEX* study, presented at the 2006 Annual European Congress of Rheumatology (EULAR) [Amsterdam, The Netherlands; June 2006], showed for the first time, that rituximab [MabThera, Rituxan], in combination with methotrexate, significantly reduces joint erosion and joint space narrowing in patients with rheumatoid arthritis (RA) who have not responded to prior tumour necrosis factor (TNF) antagonist-based therapy. Rituximab, the first and only CD20-positive B-cell targeted therapy for RA, is the first drug to achieve such results in patients with an inadequate response to currently available treatments.

Related Topics

    loading  Loading Related Articles